Other Guidelines | Page 3 | European Cystic Fibrosis Society (ECFS)

Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy

Rapid lung function decline in adults with early-stage cystic fibrosis lung disease

Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity

Exploring the implications of different approaches to estimate centre-level adherence using objective adherence data in an adult cystic fibrosis centre – a retrospective observational study

Glycaemic control and FEV1 recovery during pulmonary exacerbations in paediatric cystic fibrosis-related diabetes

Infection with Prevotella nigrescens induces Toll-like Receptor 2 signalling and low levels of p65 mediated inflammation in Cystic Fibrosis bronchial epithelial cells

The role of endothelial cells in cystic fibrosis

Ivacaftor in Cystic Fibrosis With Residual Function: Lung Function Results From an N-of-1 Study

Infection Prevention and Control in Patients With Cystic Fibrosis (CF): Results From a Survey in 35 German CF Treatment Centers

Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials

first
previous
1
2
3
4
5
6
7
8
9
…
next
last